Company intelligence / Profile preview

CStone Pharmaceuticals

Ownership: Private
Development stage: Commercial

Overview

CStone has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. Their pipeline includes 16 promising candidates in various stages of development.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)multispecific antibodiesimmunotherapiesprecision medicinesmonoclonal antibodiestrispecific antibodiesradionuclide drug conjugates (RDC)
Industry: Biotech

Drug pipeline

27 assets

sugemalimab

26 more assets in the full pipeline.

Partnerships

Hengrui

Beyond the preview

Go deeper on CStone Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CStone Pharmaceuticals.